DaVita (NYSE:DVA) Releases FY 2024 Earnings Guidance

DaVita (NYSE:DVA) updated its FY 2024 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 9.000-9.800 for the period, compared to the consensus estimate of 9.010. The company issued revenue guidance of -.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. TheStreet upgraded shares of DaVita from a c+ rating to a b- rating in a research note on Wednesday, February 7th. UBS Group boosted their target price on shares of DaVita from $113.00 to $134.00 and gave the company a buy rating in a research note on Wednesday, February 14th. Barclays boosted their target price on shares of DaVita from $133.00 to $150.00 and gave the company an equal weight rating in a research note on Monday. Truist Financial upped their price target on shares of DaVita from $130.00 to $135.00 and gave the stock a hold rating in a research report on Tuesday, February 20th. Finally, StockNews.com upgraded shares of DaVita from a buy rating to a strong-buy rating in a research report on Thursday, April 25th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, DaVita presently has an average rating of Moderate Buy and a consensus price target of $121.33.

DaVita Trading Up 1.8 %

DaVita stock traded up $2.42 during trading hours on Monday, reaching $136.87. 1,433,893 shares of the company’s stock traded hands, compared to its average volume of 846,295. The company has a debt-to-equity ratio of 7.95, a quick ratio of 1.37 and a current ratio of 1.43. DaVita has a fifty-two week low of $71.51 and a fifty-two week high of $145.04. The firm has a market capitalization of $12.00 billion, a price-to-earnings ratio of 15.49, a PEG ratio of 1.17 and a beta of 1.04. The firm’s 50 day moving average is $133.71 and its 200-day moving average is $113.08.

DaVita (NYSE:DVA) last released its earnings results on Thursday, May 2nd. The company reported $2.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.95 by $0.43. DaVita had a net margin of 6.61% and a return on equity of 68.52%. The company had revenue of $3.07 billion for the quarter, compared to the consensus estimate of $3.03 billion. During the same period in the prior year, the company posted $1.58 EPS. The company’s revenue was up 6.9% compared to the same quarter last year. On average, analysts predict that DaVita will post 9.49 earnings per share for the current year.

Insider Buying and Selling at DaVita

In other news, CEO Javier Rodriguez sold 67,603 shares of the company’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $126.11, for a total value of $8,525,414.33. Following the completion of the sale, the chief executive officer now directly owns 488,697 shares of the company’s stock, valued at approximately $61,629,578.67. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CEO Javier Rodriguez sold 67,603 shares of the company’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $126.11, for a total value of $8,525,414.33. Following the completion of the sale, the chief executive officer now directly owns 488,697 shares of the company’s stock, valued at approximately $61,629,578.67. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Michael David Staffieri sold 29,488 shares of the company’s stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $119.81, for a total value of $3,532,957.28. Following the completion of the sale, the chief operating officer now directly owns 37,687 shares of the company’s stock, valued at $4,515,279.47. The disclosure for this sale can be found here. In the last three months, insiders have sold 134,540 shares of company stock worth $16,551,071. Company insiders own 1.40% of the company’s stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.